Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)--Dec 10, 2023--

Related Keywords

United States ,Massachusetts ,San Diego ,California ,Waltham ,Delaware ,American ,Kaplan Meier ,Michaela Metzger ,Sharon Klahre ,Daniel Wolff ,Pabloj Cagnoni ,Exchange Commission ,Linkedin ,Drug Administration ,Head Of Research ,Company On Twitter ,Professor At University Hospital Regensburg ,Syndax Pharmaceuticals Nasdaq ,Syndax Pharmaceuticals ,American Society Of Hematology Annual Meeting ,Development Incyte ,Plenary Scientific Session ,American Society ,Hematology Annual Meeting ,Lee Symptom Scale ,Chief Executive Officer ,Senior Physician ,University Hospital ,Biologics License Application ,Orphan Drug Designation ,Modified Lee Symptom ,Private Securities Litigation Reform Act ,Immunology Insights ,Real World Treatment ,Incyte Contacts ,Business Wire ,National Business ,